Inclisiran is a small interfering RNA (siRNA) that prevents the production of the PCSK9 protein in the liver. By silencing the PCSK9 gene, it dramatically increases the liver's ability to clear LDL cholesterol from the blood. Reducing cumulative, lifelong exposure to LDL-C is a primary strategy for preventing atherosclerotic cardiovascular disease (ASCVD), a major driver of age-related morbidity and mortality.
Verdict
A powerful, long-acting tool for profound LDL cholesterol reduction.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$0 - $6500
Protocol
- A single 284mg subcutaneous injection administered twice per year after initial loading doses.
Flags
- Injection site reactions (pain, redness, rash) are the most common side effects.
- Long-term cardiovascular outcomes data is still being collected (ORION-4 trial).
- High cost and insurance hurdles can be significant barriers to access.
- Currently approved for patients with clinical ASCVD or heterozygous familial hypercholesterolemia.